A Multi-Centre, Double-Blind, Randomised, Parallel Group, Escitalopram Controlled Phase III-B Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR TM) as Monotherapy in the Treatment of Adult Patients With Agitated Major Depressive Disorder.

Trial Profile

A Multi-Centre, Double-Blind, Randomised, Parallel Group, Escitalopram Controlled Phase III-B Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR TM) as Monotherapy in the Treatment of Adult Patients With Agitated Major Depressive Disorder.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2014

At a glance

  • Drugs Quetiapine (Primary) ; Escitalopram
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms Quietude
  • Most Recent Events

    • 28 Jan 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 03 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top